Clinical updates, including trial initiations, enrollment status and data readouts and publications: Allegro, Ambrx, Angion, Antibe, Eli Lilly, Evotec, Fate, Jacobio, Janssen, Kiniksa, Lumosa, Lutris, Rhythm, Springworks.
Outlook Therapeutics Inc. CEO Russell Trenary said positive results from the phase III study called Norse Two represent “the final step we need” to proceed with the BLA in the first quarter of next year for an ophthalmic formulation of the VEGF binder bevacizumab to treat wet age-related macular degeneration (AMD).
Because a safety threshold was exceeded in its study of the company’s lead candidate, otenaproxesul, Antibe Therapeutics Inc. said it has placed testing of the anti-inflammatory drug on a required pause.
LONDON – The U.K. has set up the first randomized controlled trial of COVID-19 vaccines in pregnant women, to assess different dosing schedules. The aim is to find the balance between longer intervals that are known to spur a greater immune response, against shorter intervals that provide faster protection.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: 89bio, Biogen, Biophytis, Cytokinetics, Flugen, Humanigen, Ionis, Moderna, Novartis, Prometheus, Servier, Zentalis.
LONDON – More than six years after the technical specification was agreed, the EMA clinical trial information system (CTIS) has cleared the final hurdle and can go live in January 2022, after notice of approval was published in the EU Official Journal on Saturday July 31. The approval, following an independent audit of the system, was the spur for the EMA to intensify the training program it is putting in place for trial sponsors and national regulators, to ensure CTIS’ successful implementation.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alector, Astrazeneca, Beigene, Biogen, Cyclo, Enyo, Lilly, Optinose, RDIF, Vaxart.
Annovis Bio Inc. presented new clinical efficacy and biomarker data from two phase II studies of its lead candidate, ANVS-401 (posiphen), at the 2021 Alzheimer's Association International Conference (AAIC) that saw the stock sink soon afterward. The Berwyn, Pa.-based company’s shares (NYSE:ANVS) took a powerful hit as shares had plunged a dramatic 60% to close at $43.50 each on July 29.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alx, Arca, Ascletis, Astrazeneca, Clarity, Disc, Eccogene, Enyo, Hutchmed, Karyopharm, Kintor, Mersana, Mind Medicine, Zucara, Zymeworks.
RSS
